This is a European multicenter study of 90Yttrium-Ibritumomab Tiuxetan (90Y-Ibritumomab
Tiuxetan) (Zevalin®) as a front line therapy for patients with follicular lymphoma grade
I-IIIa and stage III-IV (as well as for selected patients with extended abdominal stage II).
For patients with complete clinical remission but persistent molecular disease subsequent to
90Y-Ibritumomab Tiuxetan treatment a consolidation immunotherapy with Rituximab is added, to
eradicate minimal residual disease.